Related Experiment Videos
Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
W F Keane1, J V St Peter, B L Kasiske
1Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis.
Insights
Nephrotic syndrome causes lipid abnormalities, increasing atherosclerosis risk. These changes persist with chronic proteinuria, highlighting the need for research into cardiac and renal disease links.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Lipidology
Background:
- Nephrotic syndrome is linked to dyslipidemia, including elevated LDL cholesterol and altered HDL subclasses.
- These lipid changes are associated with atherosclerosis risk and can worsen with chronic nephrotic range proteinuria.
- Existing data on the link between lipid abnormalities and cardiovascular disease in nephrotic syndrome is limited.
Purpose of the Study:
- To investigate the relationship between lipid abnormalities and cardiovascular disease in patients with nephrotic syndrome.
- To explore the correlation between lipid changes and progressive renal injury in chronic nephrotic syndrome.
- To identify gaps in knowledge regarding therapeutic interventions for cardiac and renal complications.
Main Methods:
- The study reviews existing literature and experimental data on lipid profiles in nephrotic syndrome.
- It highlights the lack of prospective studies and clinical trials in this patient population.
- Epidemiological data correlating lipid changes with renal disease progression is noted as incomplete.
Main Results:
- Nephrotic syndrome is characterized by increased total and LDL cholesterol, and reduced HDL2 subfractions.
- Chronic proteinuria leads to persistent lipid abnormalities, including elevated lipoprotein (a) and very-low-density lipoprotein.
- These persistent lipid changes may increase the risk of atherosclerosis and cardiovascular disease.
Conclusions:
- Significant data gaps exist regarding the long-term cardiovascular and renal consequences of lipid abnormalities in chronic nephrotic syndrome.
- Prospective studies and therapeutic trials are needed to clarify these relationships and guide clinical management.
- Further research is crucial to understand the impact of hyperlipidemia on renal injury progression.
Abstract:
The development of the nephrotic syndrome is associated with a lipid profile characterized by increased total and low density lipoprotein cholesterol. Although total high density lipoprotein (HDL) values may be in the normal range, there is frequently abnormalities of HDL subclasses, with reduction of the mature HDL2 subfraction. While these lipid changes may be considered a risk for atherosclerosis, they revert to normal with remission of the nephrotic syndrome. However, with chronic nephrotic range proteinuria, these abnormalities persist and may also be associated with increased levels of lipoprotein (a), increased levels of very light density lipoprotein and further reductions in HDL. These factors could all contribute to greater risk for atherosclerosis. Although coronary artery disease is frequently seen in patients with end-stage renal disease, and many uncontrolled studies in patients with chronic nephrotic syndrome have suggested an increased prevalence of cardiovascular disease, no prospective studies to evaluate relationship between lipid abnormalities and cardiac disease have been performed in patients with the nephrotic syndrome. Recent experimental data have also suggested a relationship between hyperlipidemia and progressive renal injury. Unfortunately, human epidemiological data are incomplete in correlating lipid changes with renal disease in patients with chronic nephrotic syndrome. No therapeutic trials have tested whether or not pharmacologic interventions will benefit either the cardiac or renal disease that ensues in patients with chronic persistent nephrotic syndrome. Thus, considerably more data are needed to help clarify this important area.